Abilify MyCite
The news comes months after reports that the company had furloughed staff and couldn't secure additional funding for its-ingestible sensor business.
The pharma company walks away with the full license for Proteus' mental health treatment adherence technology.
As the Abilify MyCite platform nears a full rollout, the companies said they are looking forward to employing the technology toward additional mental health therapies.
The two companies are planning a limited initial deployment to gather additional real-world data before a wider release.
Stakeholders across healthcare are beginning to weigh the benefits and challenges digital therapeutics could bring to their businesses, and pharma is no exception.
It’s still the early days, but the FDA’s approval of Proteus Digital Health and Otsuka Pharmaceuticals’ Abilify MyCite has changed the discussion of digital technology in healthcare.